// App-Quantinova.ai

SAT0168 : ONLY ONE THIRD OF REAL WORLD LUPUS PATIENTS MEET ELIGIBILITY CRITERIA FOR CLINICAL TRIALS: IMPLICATIONS FOR TRIAL VALIDITY AND GENERALISABILITY

Researchers

Presenter

  • S. Dyball

Principal Investigators

  • S. Collinson

  • E. Sutton

  • E. Mccarthy

  • B. Parker

  • I. N. Bruce

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • The Kellgren Centre for Rheumatology, CMFT, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Infectious Diseases (ID)

  • Autoimmune (AI)

Disease

  • Basal cell carcinoma

  • Hepatitis B

  • Solid malignancies

  • Lupus

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • GSK and Sanofi

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved